Gel4Med
Gel4Med is a commercial-stage company pioneering the use of smart, bioinspired materials to address major challenges in medicine. Founded out of Harvard Innovation Labs, Gel4Med leverages its proprietary Smart Materials Platform™ (SMP™) to develop advanced therapeutics and devices, with a mission to enhance health outcomes and access for all patients. The company is committed to creating novel biomaterials that improve regenerative medicine and surgical solutions, and has achieved significant milestones including FDA clearance for its lead wound care product, G4Derm™ Plus.
Gel4Med
1660 Soldiers Field Road, STE 7, #1063, Brighton MA 02135
What We Do
A patented, nano-engineered bioengineering platform that creates peptide-based materials mimicking natural extracellular matrices and proteins. SMP™ enables the development of highly customizable, therapeutic biomaterials for regenerative medicine and surgical applications, offering features like adaptable form factors, antimicrobial capability, controlled delivery, customizable biodegradability, biomechanical tunability, and stimuli responsiveness.
An advanced wound care system based on Gel4Med’s SMP™ technology. G4Derm™ Plus is a flowable biomimetic matrix delivered via a prefilled syringe with a flexible applicator, forming a 3D scaffold that mimics human extracellular matrix and serves as an antibacterial barrier. It is designed for the management of complex wounds, supporting tissue regrowth, bioburden protection, and superior biocompatibility. FDA-cleared for use in various wound types including diabetic ulcers, surgical wounds, and burns.
Digital Health Technologies
Routes of Administration
Services
Key People
Co-Founder & CEO
Associate Director- Product Development
Scientist- Biomaterials
Scientist- Cell & Tissue Biology
Clinical Operations Manager
Senior Product Manager
News & Updates
Gel4Med received its first FDA 510(k) market clearance for G4Derm™/G4Derm™ Plus, marking a significant milestone for its lead wound care asset.
Gel4Med was awarded highly competitive funding from the NIH SBIR program to advance its wound care and surgical reconstruction portfolio.
Gel4Med received significant funding from the NIH CRP program for the commercial launch of its lead asset.
Gel4Med and the University of Miami were awarded significant funding from the CDMRP/DoD for collaborative research on novel spinal cord injury treatments.
G4Derm™ Plus Biomimetic Matrix was featured in the August 2025 issue of Podiatry Management Magazine, highlighting its wound healing capabilities.
A case series published by Massachusetts General Hospital / Harvard Medical School highlighted rapid healing of diabetic foot ulcers using G4Derm™ Plus.